Filters: keyword is Algorithms [Clear All Filters]
- 2008
Pharmacokinetic/pharmacodynamic modelling of the EEG effects of opioids: the role of complex biophase distribution kinetics,
Eur J Pharm Sci, vol. 34, no. 2-3, pp. 149-63.
Pharmacokinetic-pharmacodynamic modelling of fluvoxamine 5-HT transporter occupancy in rat frontal cortex,
Br J Pharmacol, vol. 154, no. 6, pp. 1369-78.
Pharmacokinetic-pharmacodynamic modeling of the effectiveness and safety of buprenorphine and fentanyl in rats,
Pharm Res, vol. 25, no. 1, pp. 183-93.
Extensions to the visual predictive check to facilitate model performance evaluation,
J Pharmacokinet Pharmacodyn, vol. 35, no. 2, pp. 185-202.
- 2007
Pharmacokinetic-pharmacodynamic modelling of S(-)-atenolol in rats: reduction of isoprenaline-induced tachycardia as a continuous pharmacodynamic endpoint,
Br J Pharmacol, vol. 151, no. 3, pp. 356-66.
Influence of biophase distribution and P-glycoprotein interaction on pharmacokinetic-pharmacodynamic modelling of the effects of morphine on the EEG,
Br J Pharmacol, vol. 151, no. 5, pp. 713-20.
Population pharmacokinetic modelling of non-linear brain distribution of morphine: influence of active saturable influx and P-glycoprotein mediated efflux,
Br J Pharmacol, vol. 151, no. 5, pp. 701-12.
Mechanism-based pharmacokinetic-pharmacodynamic modelling of the reversal of buprenorphine-induced respiratory depression by naloxone : a study in healthy volunteers,
Clin Pharmacokinet, vol. 46, no. 11, pp. 965-80.
- 2006
Population pharmacodynamic modelling of lorazepam- and midazolam-induced sedation upon long-term continuous infusion in critically ill patients,
Eur J Clin Pharmacol, vol. 62, no. 3, pp. 185-94.
A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus,
J Pharmacokinet Pharmacodyn, vol. 33, no. 3, pp. 313-43.
- 2005
Pharmacokinetic/pharmacodynamic modelling of the anti-hyperalgesic and anti-nociceptive effect of adenosine A1 receptor partial agonists in neuropathic pain,
Eur J Pharmacol, vol. 514, no. 2-3, pp. 131-40.
- 2004
Compartmental modeling of transdermal iontophoretic transport: I. In vitro model derivation and application,
Pharm Res, vol. 21, no. 11, pp. 1974-84.
Transdermal iontophoresis of rotigotine across human stratum corneum in vitro: influence of pH and NaCl concentration,
Pharm Res, vol. 21, no. 5, pp. 844-50.
Population pharmacokinetic modeling of blood-brain barrier transport of synthetic adenosine A1 receptor agonists,
J Pharmacol Exp Ther, vol. 311, no. 3, pp. 1138-46.
- 2003
Characterization of the pharmacokinetics, brain distribution, and therapeutic efficacy of the adenosine A1 receptor partial agonist 2'-deoxy-N6-cyclopentyladenosine in sarin-poisoned rats,
Toxicol Appl Pharmacol, vol. 192, no. 1, pp. 86-94.
Mechanism-based pharmacokinetic/pharmacodynamic modeling of the electroencephalogram effects of GABAA receptor modulators: in vitro-in vivo correlations,
J Pharmacol Exp Ther, vol. 304, no. 1, pp. 88-101.
- 2002
Mechanism-based pharmacokinetic-pharmacodynamic modeling of concentration-dependent hysteresis and biphasic electroencephalogram effects of alphaxalone in rats,
J Pharmacol Exp Ther, vol. 302, no. 3, pp. 1158-67.
Neuroactive steroids differ in potency but not in intrinsic efficacy at the GABA(A) receptor in vivo,
J Pharmacol Exp Ther, vol. 303, no. 2, pp. 616-26.
A competitive interaction model predicts the effect of WAY-100,635 on the time course of R-(+)-8-hydroxy-2-(di-n-propylamino)tetralin-induced hypothermia,
J Pharmacol Exp Ther, vol. 300, no. 1, pp. 330-8.
- 2001
Pharmacokinetic-pharmacodynamic modelling in the early development phase of anti-psychotics: a comparison of the effects of clozapine, S 16924 and S 18327 in the EEG model in rats,
Br J Pharmacol, vol. 132, no. 1, pp. 151-8.
- 1999
Characterization of the pharmacodynamic interaction between parent drug and active metabolite in vivo: midazolam and alpha-OH-midazolam,
J Pharmacol Exp Ther, vol. 289, no. 2, pp. 1067-74.
Rate of change of blood concentrations is a major determinant of the pharmacodynamics of midazolam in rats,
Br J Pharmacol, vol. 127, no. 1, pp. 227-35.
- 1996
Population pharmacokinetics of ceftazidime in cystic fibrosis patients analyzed by using a nonparametric algorithm and optimal sampling strategy,
Antimicrob Agents Chemother, vol. 40, no. 5, pp. 1091-7.
- 1991
A system approach to pharmacodynamics. III: An algorithm and computer program, COLAPS, for pharmacodynamic modeling,
J Pharm Sci, vol. 80, no. 5, pp. 488-95.



